New: SPNS Supporting Replication of Housing Interventions Request For Proposal (RFP)

SPNS Supporting Replication of Housing Interventions Request For Proposal (RFP)
SPNS Supporting Replication (SURE) of Housing Interventions Request For Proposal (RFP)

A Request for Proposal (RFP) is now available to Ryan White HIV/AIDS Program (RWHAP) service providers for a Special Project of National Significance (SPNS) program titled Supporting Replication (SURE) of Housing Interventions. It includes funding for up to 10 implementation sites that will implement and adapt housing-related intervention strategies for three priority populations of people with HIV experiencing unstable housing.

The purpose of the SURE Housing initiative is to implement and adapt housing-related intervention strategies for three priority populations of people with HIV experiencing unstable housing, who often have the highest HIV-related disparities:

1) people who identify as lesbian, gay, bisexual, transgender, and queer or questioning (LGBTQ+);
2) youth and young adults (aged 18-24); and
3) people who have been justice-involved (defined as any person who is engaged at any point along the continuum of the criminal justice system as a defendant including arrest, incarceration, and community supervision).

The goal of this initiative is to promote the replication of effective housing interventions in the RWHAP to decrease health and housing disparities and improve health outcomes along the HIV care continuum.  This initiative will engage and retain people with HIV experiencing unstable housing in HIV medical care and support services by addressing their housing and behavioral health needs, as needed.

Serving as the Implementation and Technical Assistance Provider, the Corporation for Supportive Housing (CSH), in partnership with Collaborative Solutions, Inc (CSI), will select, issue, and monitor sub-awards of up to $250,000 per funding year for up to ten implementation sites. Sites will be funded from May 1, 2023 – July 31, 2026. CSH and CSI will provide the sites with technical assistance (TA) for implementing and adapting these interventions.

The implementation sites will also participate in a multi-site evaluation to assess the effectiveness of the interventions’ implementation and adaptation. The implementation of housing-related interventions at each site will be evaluated by the Evaluation Provider comprised of Boston University, the University of Massachusetts, Lowell, and JSI Research & Training Institute, Inc.

Additional information can be found in the Request for Proposals.

Application Details

Current RWHAP service providers are eligible to apply. Applications are due no later than 11:59pm ET on February 15, 2023. To learn more about this opportunity, register here for a live webinar taking place on January 10, 2023 at 3PM Eastern.

For more information, contact HRSA.TA@CSH.ORG.

ViiV Healthcare HIV Medications to be Discontinued as of January 1, 2024

Announcement: ViiV Healthcare HIV Medications to be Discontinued as of January 1, 2024

ViiV Logo

Last year, ViiV Healthcare (“ViiV”) released a letter notifying health care providers

that the following products will be discontinued in the United States, and will no longer be distributed by ViiV as of January 1, 2024:

  • Lexiva (fosamprenavir) 700 mg Tablets and 50 mg/ml Oral Suspension
  • Trizivir (abacavir/lamivudine/zidovudine) 300 mg/150 mg/300 mg Tablets
  • Selzentry (maraviroc) 25 mg Tablets and 75 mg Tablets
  • Tivicay (dolutegravir) 10 mg Tablets and 25 mg Tablets
  • Ziagen (abacavir) 300 mg Tablets
  • Combivir (lamivudine/zidovudine) 150 mg/300 mg Tablets
  • Epzicom (abacavir/lamivudine) 600 mg/300 mg Tablets

In addition, in the letter ViiV stated it would no longer accept new Patient Assistance Program (PAP) applications for the products listed above after 07/01/22.

For any questions or concerns, please contact the ViiV Healthcare Customer Response Center at 1-877-844-8872.

Invitation to Participate: HIV Provider Training to Address Medical Mistrust

Hands holding red ribbon

Invitation to Participate: HIV Provider Training to Address Medical Mistrust

Who should participate?

  • HIV care providers (MD, DO, NP, PA) who primarily work with Black and Latinx patients

What does participation involve?

  • Virtual training (total 4 hours) conducted by California Prevention Training Center
  • Phone interview (45 min) to provide feedback that will be used to improve the training
  • $200 gift card will be provided

Who is conducting this research?

How can I participate?

For more information, please contact Bella González

Cell: (703)-413-1100 x5793

Email: igonzale@rand.org 

Read an official message from the RAND Corporation below:

“We are a team of researchers, HIV care providers, and provider training experts from the RAND Corporation, California Prevention Training Center, and Brigham & Women’s Hospital. We are conducting a study to develop and pilot test an HIV care provider training to understand and address the impact of stigma and medical mistrust experienced by Black and Latinx consumers/patients. This research is funded by the National Institute of Health, and the study protocol has been approved by RAND’s Institutional Review Board.

If you are an HIV care providers (e.g., physician, nurse practitioner, physician assistant) who works with a substantial number of Black and Latinx HIV care consumers or patients, we would like to invite you to participate in our study and provide feedback to improve this training. The tentative dates are in mid-January 2023 (e.g., potentially during the week of 1/9) and the participation would be remote/virtual. The total time would be about 4 hours for the virtual training (via Zoom) and there will be a phone interview (45-60 min) to provide qualitative feedback and suggestions for improvement. We may schedule a long session of 4 hours or break it up into two sessions, whichever would be most convenient/manageable. Your feedback would be used to refine and improve this provider training. You will be compensated $200 for participating in the training and interview. The training will be conducted by expert trainers from California Prevention Training Center; the interview will be conducted by RAND researchers.

Your participation in the training session(s) and interview are completely voluntary. We will not identify you in any way in any of our research presentations, papers, or reports. The information you provide to us during your participation will be kept confidential. If you are interested in participating, our research staff contacting you will review this information with you at the beginning of the training and interview and can answer any questions that you have at those times.

Please enter your contact information in this Google Form here if you are interested in participating in this study. If so, we will work with you to identify a convenient time to proceed with the next steps. Please feel free to contact us to ask any questions you may have about any aspects of this study. Our study contact is Dr. Lu Dong (ldong@rand.org, 310-486-1847).

Thank you for helping with this important project.”